Alnylam Pharmaceuticals Inc (ALNY)

NASDAQ
231.01
-2.84(-1.21%)
After Hours
227.05
-3.96(-1.71%)
- Real-time Data
  • Volume:
    730,485
  • Day's Range:
    225.00 - 233.22
  • 52 wk Range:
    117.58 - 236.80

ALNY Overview

Prev. Close
233.85
Day's Range
225-233.22
Revenue
884.25M
Open
226.16
52 wk Range
117.58-236.8
EPS
-8.17
Volume
730,485
Market Cap
27.73B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
975,335
P/E Ratio
-27.35
Beta
0.737
1-Year Change
17.54%
Shares Outstanding
120,026,559
Next Earnings Date
Oct 27, 2022
What is your sentiment on Alnylam?
or
Market is currently closed. Voting is open during market hours.

Alnylam Pharmaceuticals Inc Analysis

Alnylam Pharmaceuticals Inc Company Profile

Alnylam Pharmaceuticals Inc Company Profile

Employees
1453

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It is developing therapeutics based on ribonucleic acid interference (RNAi). Its pipeline includes four products and multiple late and early-stage investigational RNAi therapeutics, that is focused in four strategic therapeutic areas (STArs): Genetic Medicines; Cardio-Metabolic Diseases; Hepatic Infectious Diseases; and CNS/Ocular Diseases. Its RNAi-based medicines include ONPATTRO (patisiran), GIVLAARI (givosiran), OXLUMO (lumasiran) and Leqvio (inclisiran). ONPATTRO is an intravenously administered RNAi therapeutic targeting transthyretin amyloidosis. GIVLAARI is used to reduce induced liver aminolevulinic acid synthase 1 messenger RNA (mRNA), to reduce toxins associated with attacks and other disease manifestations of acute hepatic porphyria. OXLUMO is an RNAi therapeutic targeting hydroxyacid oxidase 1 for the treatment of primary hyperoxaluria type 1. Leqvio is used for the treatment of adults with hypercholesterolemia.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyBuyStrong BuyStrong BuyStrong Buy
Technical IndicatorsStrong BuyBuyBuyStrong BuyStrong Buy
SummaryStrong BuyBuyStrong BuyStrong BuyStrong Buy
  • Junk
    0
    • Give the anti-corona spray from marinomed-biotech some VC and invest in a pharma company which is heading to the moon:https://www.investing.com/equities/marinomed-biotech-agStudies are proving that the patented method of marinomed prevents infection with all Corona varietis including mutants. It also prevents other virus infections. They have many patents.  Do some good and get rich
      0
      • Buying 200 mor at 140
        0
        • I'm buying another 200 shares at 140
          0
          • good short, add more with sell stop @ $124.75. Risk mngt @ previous highs
            0
            • 34.000.000 $ singol transaction yesterday at 16;22
              0
              • In after-hours
                0
            • Ready to start?
              0